CA3185888A1 - Brm targeting compounds and associated methods of use - Google Patents
Brm targeting compounds and associated methods of useInfo
- Publication number
- CA3185888A1 CA3185888A1 CA3185888A CA3185888A CA3185888A1 CA 3185888 A1 CA3185888 A1 CA 3185888A1 CA 3185888 A CA3185888 A CA 3185888A CA 3185888 A CA3185888 A CA 3185888A CA 3185888 A1 CA3185888 A1 CA 3185888A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- crlarlb
- groups
- rla
- nr1c
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063036811P | 2020-06-09 | 2020-06-09 | |
| US63/036,811 | 2020-06-09 | ||
| PCT/US2021/036664 WO2021252666A1 (en) | 2020-06-09 | 2021-06-09 | Brm targeting compounds and associated methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3185888A1 true CA3185888A1 (en) | 2021-12-16 |
Family
ID=76731093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3185888A Pending CA3185888A1 (en) | 2020-06-09 | 2021-06-09 | Brm targeting compounds and associated methods of use |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11702423B2 (enExample) |
| EP (2) | EP4161935B1 (enExample) |
| JP (1) | JP2023529908A (enExample) |
| KR (1) | KR20230037549A (enExample) |
| CN (1) | CN115867554B (enExample) |
| AU (1) | AU2021289730A1 (enExample) |
| BR (1) | BR112022025061A2 (enExample) |
| CA (1) | CA3185888A1 (enExample) |
| DK (1) | DK4161935T3 (enExample) |
| ES (1) | ES3034380T3 (enExample) |
| FI (1) | FI4161935T3 (enExample) |
| IL (1) | IL298933B2 (enExample) |
| MX (1) | MX2022015732A (enExample) |
| PL (1) | PL4161935T3 (enExample) |
| PT (1) | PT4161935T (enExample) |
| WO (1) | WO2021252666A1 (enExample) |
| ZA (1) | ZA202213711B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US12624044B2 (en) | 2019-06-10 | 2026-05-12 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| US11679109B2 (en) | 2019-12-23 | 2023-06-20 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2021133917A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| WO2022099117A1 (en) * | 2020-11-06 | 2022-05-12 | Prelude Therapeutics Incorporated | Brm targeting compounds and associated methods of use |
| US12606568B2 (en) | 2020-12-09 | 2026-04-21 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2023278402A1 (en) * | 2021-06-28 | 2023-01-05 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| JP2024533990A (ja) * | 2021-08-09 | 2024-09-18 | ジェネンテック， インコーポレイテッド | Ｂｒｍの調節に使用するためのフェノール誘導体 |
| AU2023270000A1 (en) * | 2022-05-10 | 2024-11-28 | Foghorn Therapeutics Inc. | Pyrazine derivatives and uses thereof |
| JP2025521091A (ja) * | 2022-05-10 | 2025-07-08 | プレリュード・セラピューティクス・インコーポレイテッド | がんの治療のためのｓｍａｒｃａ４タンパク質分解因子としての６，６ａ，７，８，９，１０－ヘキサヒドロ－５ｈ－ピラジノ［１’，２’：４，５］ピラジノ［２，３－ｃ］ピリダジン誘導体 |
| WO2024064316A1 (en) * | 2022-09-23 | 2024-03-28 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 inhibitors and uses thereof |
| WO2024064328A1 (en) * | 2022-09-23 | 2024-03-28 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 degraders and uses thereof |
| AU2023356925A1 (en) * | 2022-10-03 | 2025-04-24 | Prelude Therapeutics Incorporated | Improved treatment of cancers using combinations of SMARCA2 degraders and KRAS targeting therapies |
| EP4695250A1 (en) | 2023-04-12 | 2026-02-18 | Aurigene Oncology Limited | Tetracyclic compounds as smarca2 and/or smarca4 degraders |
| WO2025076351A1 (en) | 2023-10-04 | 2025-04-10 | Prelude Therapeutics Incorporated | Combination treatment regimens - smarca2 degrader with gemcitabine |
| US20250114354A1 (en) | 2023-10-04 | 2025-04-10 | Prelude Therapeutics Incorporated | Combination treatment regimens - smarca2 degrader with pd-1 inhibitors |
| US20260115189A1 (en) | 2023-10-04 | 2026-04-30 | Prelude Therapeutics Incorporated | Combination Treatment Regimens - SMARCA2 Degrader With Taxane Anticancer Agent |
| WO2025106482A1 (en) * | 2023-11-13 | 2025-05-22 | Oncopia Therapeutics, Inc. D/B/A Sk Life Science Labs | Compounds and compositions as smarca2/4 degraders and uses thereof |
| WO2025193454A1 (en) | 2024-03-01 | 2025-09-18 | Prelude Therapeutics Incorporated | Brm and brg1 targeting antibody-drug conjugates and methods of use thereof |
| WO2026039756A1 (en) * | 2024-08-16 | 2026-02-19 | Prelude Therapeutics Incorporated | Methods of treating cancer using a smarca2 degrader |
| WO2026090411A1 (en) * | 2024-10-23 | 2026-04-30 | Prelude Therapeutics Incorporated | Brm and brg1 targeting compounds and associated methods of use |
| CN119638700B (zh) * | 2024-11-01 | 2025-11-14 | 中科中山药物创新研究院 | 一种nsd2降解剂及其应用 |
| WO2026152359A1 (en) * | 2025-01-17 | 2026-07-23 | Prelude Therapeutics Incorporated | Polymorphic compounds and uses thereof |
| WO2026156670A1 (en) | 2025-01-24 | 2026-07-30 | Prelude Therapeutics Incorporated | Processes for making smarca2 degraders |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5350395A (en) | 1986-04-15 | 1994-09-27 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
| US4748982A (en) | 1987-01-06 | 1988-06-07 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| CA1322628C (en) | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Expandable intraluminal graft |
| US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
| US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
| US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| GB2554071A (en) | 2016-09-14 | 2018-03-28 | Univ Dundee | Small molecules |
| IL325835A (en) | 2016-12-23 | 2026-03-01 | Univ Yale | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| IL300417A (en) | 2017-01-26 | 2023-04-01 | Arvinas Operations Inc | Bifunctional benzothiophene compounds, preparations containing them and their use in therapy |
| WO2019084026A1 (en) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE |
| WO2019084030A1 (en) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE |
| AU2019249849C1 (en) | 2018-04-01 | 2022-09-29 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| US20220324880A1 (en) | 2019-06-10 | 2022-10-13 | Kymara Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| US20230087825A1 (en) | 2019-06-10 | 2023-03-23 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| US12624044B2 (en) | 2019-06-10 | 2026-05-12 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2021133917A1 (en) * | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| US11679109B2 (en) * | 2019-12-23 | 2023-06-20 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2022099117A1 (en) * | 2020-11-06 | 2022-05-12 | Prelude Therapeutics Incorporated | Brm targeting compounds and associated methods of use |
-
2021
- 2021-06-09 PT PT217368901T patent/PT4161935T/pt unknown
- 2021-06-09 WO PCT/US2021/036664 patent/WO2021252666A1/en not_active Ceased
- 2021-06-09 CN CN202180049461.6A patent/CN115867554B/zh active Active
- 2021-06-09 BR BR112022025061A patent/BR112022025061A2/pt unknown
- 2021-06-09 PL PL21736890.1T patent/PL4161935T3/pl unknown
- 2021-06-09 CA CA3185888A patent/CA3185888A1/en active Pending
- 2021-06-09 EP EP21736890.1A patent/EP4161935B1/en active Active
- 2021-06-09 EP EP25173100.6A patent/EP4570319A3/en active Pending
- 2021-06-09 FI FIEP21736890.1T patent/FI4161935T3/fi active
- 2021-06-09 ES ES21736890T patent/ES3034380T3/es active Active
- 2021-06-09 MX MX2022015732A patent/MX2022015732A/es unknown
- 2021-06-09 US US17/343,341 patent/US11702423B2/en active Active
- 2021-06-09 DK DK21736890.1T patent/DK4161935T3/da active
- 2021-06-09 JP JP2022575824A patent/JP2023529908A/ja active Pending
- 2021-06-09 KR KR1020237000892A patent/KR20230037549A/ko active Pending
- 2021-06-09 AU AU2021289730A patent/AU2021289730A1/en active Pending
-
2022
- 2022-12-08 IL IL298933A patent/IL298933B2/en unknown
- 2022-12-19 ZA ZA2022/13711A patent/ZA202213711B/en unknown
-
2023
- 2023-05-15 US US18/317,352 patent/US20240018158A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4161935A1 (en) | 2023-04-12 |
| IL298933B1 (en) | 2026-04-01 |
| IL298933B2 (en) | 2026-08-01 |
| US20240018158A1 (en) | 2024-01-18 |
| BR112022025061A2 (pt) | 2023-01-31 |
| EP4570319A2 (en) | 2025-06-18 |
| ZA202213711B (en) | 2026-04-29 |
| EP4161935B1 (en) | 2025-05-21 |
| AU2021289730A1 (en) | 2023-01-19 |
| DK4161935T3 (da) | 2025-08-18 |
| EP4570319A3 (en) | 2025-08-20 |
| MX2022015732A (es) | 2023-02-13 |
| JP2023529908A (ja) | 2023-07-12 |
| WO2021252666A1 (en) | 2021-12-16 |
| US11702423B2 (en) | 2023-07-18 |
| AU2021289730A8 (en) | 2023-02-02 |
| US20220033409A1 (en) | 2022-02-03 |
| KR20230037549A (ko) | 2023-03-16 |
| IL298933A (en) | 2023-02-01 |
| PL4161935T3 (pl) | 2025-09-08 |
| CN115867554B (zh) | 2025-09-02 |
| FI4161935T3 (fi) | 2025-08-19 |
| ES3034380T3 (en) | 2025-08-18 |
| CN115867554A (zh) | 2023-03-28 |
| PT4161935T (pt) | 2025-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4161935B1 (en) | Brm targeting compounds and associated methods of use | |
| EP4010080B1 (en) | Heterocyclic compounds for use in the treatment of cancer | |
| CA3200685A1 (en) | Brm targeting compounds and associated methods of use | |
| KR20210089662A (ko) | 골수 세포 백혈병-1 (mcl-1) 단백질의 억제제로서 스피로-술폰아미드 유도체 | |
| US20230365576A1 (en) | BRM Targeting Compounds And Associated Methods Of Use | |
| AU2023264018A1 (en) | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders | |
| US20240190886A1 (en) | BRM Targeting Compounds and Associated Methods of Use | |
| CN119053600A (zh) | 用于治疗癌症的杂环化合物 | |
| CA3259017A1 (en) | KAT6 Targeting Compounds with Ubiquitin Ligasis Bonding Fraction | |
| CN118632841A (zh) | 用于治疗癌症的杂环化合物 | |
| IL319211A (en) | Triazine compounds and their uses | |
| US20240336612A1 (en) | BRM Targeting Compounds And Associated Methods Of Use | |
| HK40128204A (en) | Brm targeting compounds and associated methods of use | |
| EA048707B1 (ru) | Brm направленные соединения и связанные способы применения | |
| EA050840B1 (ru) | Brm направленные соединения и связанные способы применения | |
| HK40078801A (en) | Heterocyclic compounds for use in the treatment of cancer | |
| HK40078801B (en) | Heterocyclic compounds for use in the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250602 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250602 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250602 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250604 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250815 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250815 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250815 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250815 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250818 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250912 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250912 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251124 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260504 |